| HOME >> BIOLOGY >> TECHNOLOGY |
SUMMARY OF FINANCIAL HIGHLIGHTS
($000 of U.S. dollars except shares outstanding and per share amounts)
CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
OPERATIONAL DATA
Three Months Ended Nine Months Ended
March 31, March 31, March 31, March 31,
2009 2008 2009 2008
(unaudited) (unaudited) (unaudited) (unaudited)
Net sales $2,032 $1,951 $6,029 $6,455
Gross profit 1,144 1,140 3,404 3,627
Total operating
expenses 1,205 1,203 3,616 3,464
Operating income
(loss) (61) (63) (211) 163
Net loss (454) (352) (1,064) (1,101)
Weighted average
shares
outstanding 30,286,922 26,452,150 30,219,233 23,601,550
Net loss per
share $(0.02) $(0.01) $(0.04) $(0.05)
Adjusted EBITDA $267 $123 $456 $652
SUMMARY BALANCE SHEET DATA
(in thousands)
March 31, 2009 June 30, 2008
(unaudited) (audited)
Cash $665 $1,520
Working capital 2,150 2,889
Total assets 6,875
'/>"/>
| SOURCE Corgenix Medical Corporation Copyright©2009 PR Newswire. All rights reserved |